Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor‐tyrosine kinase inhibitor therapy

BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR‐TKIs) in non‐small cell lung cancer (NSCLC). However, even patients with EGFR‐sensitive mutations in NSCLC have limited efficacy with EGFR‐TKI. Studies have shown that l...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Panpan, Yang, Shaoxing, Liu, Wenjing, Qin, Haifeng, Tang, Xiuhua, Wu, Fangfang, Liu, Zeyuan, Gao, Hongjun, Liu, Xiaoqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938758/
https://www.ncbi.nlm.nih.gov/pubmed/31691525
http://dx.doi.org/10.1111/1759-7714.13216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938758/
https://www.ncbi.nlm.nih.gov/pubmed/31691525
http://dx.doi.org/10.1111/1759-7714.13216

Ejemplares similares